Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Publication year
2018Author(s)
Source
Blood, 131, 12, (2018), pp. 1275-1291ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Laboratory Medicine
Journal title
Blood
Volume
vol. 131
Issue
iss. 12
Page start
p. 1275
Page end
p. 1291
Subject
Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences; Laboratory Medicine - Radboud University Medical CenterThis item appears in the following Collection(s)
- Academic publications [242559]
- Faculty of Medical Sciences [92285]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.